CEACAM5 and cancer: Although several blood-based biomarkers, such as carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA), have been used for cancer screening in the past few decades, their sensitivity and specificity have been found to be unsatisfactory, limiting their effectiveness [5].